002099.SZ
海翔药业
SZSE · Healthcare · C 制造业 · CN
CNY 5.05
−3.63%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
34.9x
Market Cap
CNY 8.18B
MomentumView details →
1D Return
−3.63%
YTD Return
−13.30%
RSI (14)
51.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
34.9x
Market Cap
CNY 8.18B
RSI (14)
51.5
MomentumView details →
1D Return
−3.63%
YTD Return
−13.30%
Similar companies
Latest newsMore news →
Haixiang Pharmaceutical reported a net loss of 64.038 million yuan for the first half of 2026, turning from a profit in the same period last year.8d agoHaixiang Pharmaceutical's wholly-owned subsidiary Zhejiang Haixiang Chuannan Pharmaceutical received approval from China's National Medical Products Administration for its adenosine cyclophosphate API, packaged in 4kg/drum, with registration approved but GMP compliance check still required before domestic production and sales.10d ago